Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Ascendant Dx™ Appoints Dr. Patricia Beckmann as Chief Scientific Officer and Chief Business Officer; Drs. Mark Boguski and Isaac Kohane to the Scientific Advisory Board
  • USA - English


News provided by

Ascendant Dx™

May 27, 2014, 09:05 ET

Share this article

Share toX

Share this article

Share toX


Fayetteville, Ark., and Seattle, Wash. (PRWEB) May 27, 2014 -- Dr. Patricia Beckmann, a prominent scientist and inventor has been appointed to the combined roles of chief scientific officer (CSO) and chief business officer (CBO) at Ascendant Dx. In addition, Dr. Mark Boguski and Dr. Isaac Kohane have joined the Scientific Advisory Board of the company. “We are pleased to welcome such distinguished scientists and entrepreneurs into our executive and advisory rank,” says Omid Moghadam, chief executive officer, Ascendant Dx.

My background in science and business helps me identify a project with potential, validate the science and prepare the technology to become a successful commercial product. I understand what it takes to commercialize a new scientific discovery.

Post this

Patricia Beckmann, PhD is a co-inventor of the rheumatoid arthritis drug, Enbrel (2012 worldwide sales over $8B) and the founder and managing director of BioStrategy, LLC, a strategic and management consultancy. She formerly was the president and executive director of the Oregon Translational Research and Development Institute (OTRADI) in Portland, Oregon.

Dr. Beckmann has excelled in scientific advancement as well as business leadership and development of proteomics-based diagnostics. She was chief scientific officer at Homestead Clinical Corporation (now Integrated Diagnostics), a startup financed by Seattle’s Accelerator focusing on proteomic biomarkers for cancer. Previously at Vulcan Capital, the investment vehicle for Microsoft co-founder Paul Allen, Beckmann was responsible for vetting biotechnology venture investment opportunities.

“My background in science and business helps me identify a project with potential, validate the science and prepare the technology to become a successful commercial product,” says Beckmann. “I understand what it takes to commercialize a new scientific discovery.”

Mark Boguski, MD, PhD is a pioneer in the fields of precision diagnostics, bioinformatics and genomics and has founded or co-founded ventures in diagnostics, medical publishing, consumer health and mobile health. Dr. Boguski serves on the faculty of Harvard Medical School and as the Chief Medical Officer of Genome Health Solutions, Inc. He founded the Genomic Medicine Initiative at Beth Israel Deaconess Medical Center (a teaching hospital of Harvard Medical School) in 2009. He has previously held faculty positions at the Johns Hopkins School of Medicine, the U.S. National Institutes of Health and as an executive in the biotechnology and pharmaceutical industries. He is a former Vice President of Novartis and has been described as a Visionary and Influencer according to the Personalized Medicine Coalition. Dr. Boguski is an elected member of the Institute of Medicine of the U.S. National Academies and a Fellow of the College of American Pathologists.

Isaac Kohane, MD, PhD is a Professor of Pediatrics and Health Sciences and Technology at Harvard Medical School. He is the Co-Director of the Center for Biomedical Informatics at HMS, and the Director of the Boston Children’s Hospital Informatics Program. He is a Fellow of the American College of Medical Informatics and of the Society of Pediatric Research, a member of the Institute of Medicine, and the American Society of Clinical Investigation.

Dr. Kohane leads multiple collaborations at HMS and it’s hospital affiliates in the study of cancer (as it relates to) and the development of the brain. Dr. Kohane also leads several NIH-funded efforts to translate genomic research into clinical practice and continues his own practice in pediatric endocrinology at Boston Children’s Hospital. His research has been the basis of several successful new ventures in diagnostics and bioinformatics.

“We are fortunate that we can count of the advice and participation of such prominent scientists and clinicians at Ascendant,” says Moghadam. “Because of their exceptional blend of experiences, we will increase our scientific capabilities, our link to the academic community and our ability to successfully bring diagnostic products we develop to market.”

Ascendant Dx, an emerging biotech company, develops high-value proteomics-based diagnostic tests. Ascendant’s tests combine the latest discoveries in proteomics with proven diagnostic platforms, aiming for tests that are simpler, more accurate and widely available. Ascendant Dx’s first product in development, MelodyDx™, is a panel of biomarkers, which distinguishes a malignant breast mass from benign tissue. Ascendant Dx, LLC is a VIC Technology Venture Development™ portfolio company.

###

Barbara Schuetze, Ascendant Dx™, http://www.ascendantdx.com, 503-977-7775, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.